10Q11.22Q11.23 Deletions and Microdeletions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Contribution of MSMB Promoter Region Gene Polymorphism to Early-Onset Prostate Cancer Risk in Mexican Males
www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 7), pp: 738-748 Research Paper Contribution of MSMB promoter region gene polymorphism to early-onset prostate cancer risk in Mexican males Silvia Juliana Trujillo-Cáceres1, Luisa Torres-Sánchez1, Ana I. Burguete-García2, Yaneth Citlalli Orbe Orihuela2, Ruth Argelia Vázquez-Salas3, Esmeralda Álvarez- Topete4 and Rocío Gómez4 1Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública (INSP), Cuernavaca, Morelos, Mexico 2Centro de Investigación en Enfermedades Infecciosas, INSP, Cuernavaca, Morelos, Mexico 3Conacyt-Centro de Investigación en Salud Poblacional, INSP, Cuernavaca, Morelos, Mexico 4Departamento de Toxicología, Cinvestav-IPN, Mexico City, Mexico Correspondence to: Luisa Torres-Sánchez, email: [email protected] Keywords: genetic polymorphisms; MSMB; prostate cancer; rs10993994; sexually transmitted diseases Received: July 13, 2018 Accepted: December 16, 2018 Published: January 22, 2019 Copyright: Trujillo-Cáceres et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Sexually transmitted infections and its contribution to prostate cancer (PC) development have been relevant in different populations. MSMB gene polymorphism (rs10993994) has exhibited an association both with PC as well as the susceptibility to sexually transmitted infections. Hitherto, these conditions have been not studied in Mexico yet, neither if sexually transmitted infections could modify the MSMB and PC association. Herein, socio-demographic features, sexually transmitted infections records, the reproductive backgrounds, and the genetic characterisation were analysed in 322 incident PC cases and 628 population healthy controls from Mexico City. -
Investigation of Modifier Genes Within Copy Number Variations in Rett Syndrome
See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/51147767 Investigation of modifier genes within copy number variations in Rett syndrome ARTICLE in JOURNAL OF HUMAN GENETICS · MAY 2011 Impact Factor: 2.53 · DOI: 10.1038/jhg.2011.50 · Source: PubMed CITATIONS DOWNLOADS VIEWS 6 89 134 15 AUTHORS, INCLUDING: Dag H Yasui Maria Antonietta Mencarelli University of California, Davis Azienda Ospedaliera Universitaria Senese 30 PUBLICATIONS 1,674 CITATIONS 58 PUBLICATIONS 962 CITATIONS SEE PROFILE SEE PROFILE Francesca Mari Janine M Lasalle Università degli Studi di Siena University of California, Davis 81 PUBLICATIONS 1,658 CITATIONS 98 PUBLICATIONS 3,525 CITATIONS SEE PROFILE SEE PROFILE Available from: Janine M Lasalle Retrieved on: 22 July 2015 Europe PMC Funders Group Author Manuscript J Hum Genet. Author manuscript; available in PMC 2012 January 01. Published in final edited form as: J Hum Genet. 2011 July ; 56(7): 508–515. doi:10.1038/jhg.2011.50. Europe PMC Funders Author Manuscripts Investigation of modifier genes within copy number variations in Rett syndrome Rosangela Artuso1,*, Filomena Tiziana Papa1,*, Elisa Grillo1, Mafalda Mucciolo1, Dag H. Yasui2, Keith W. Dunaway2, Vittoria Disciglio1, Maria Antonietta Mencarelli1, Marzia Pollazzon1, Michele Zappella3, Giuseppe Hayek4, Francesca Mari1, Alessandra Renieri1, Janine M. LaSalle2, and Francesca Ariani1 1 Medical Genetics Section, Biotechnology Department, University of Siena, Italy 2 Medical Microbiology and Immunology, Genome Center, School of Medicine, University of California, Davis, CA, USA 3 Child Neuropsychiatry, Versilia Hospital, Viareggio, Italy 4 Infantile Neuropsychiatry, Siena General Hospital, Italy Abstract MECP2 mutations are responsible for two different phenotypes in females, classical Rett syndrome and the milder Zappella variant (Z-RTT). -
DF6720-MSMB Antibody
Affinity Biosciences website:www.affbiotech.com order:[email protected] MSMB Antibody Cat.#: DF6720 Concn.: 1mg/ml Mol.Wt.: 13kDa Size: 50ul,100ul,200ul Source: Rabbit Clonality: Polyclonal Application: WB 1:500-1:2000, IHC 1:50-1:200, ELISA(peptide) 1:20000-1:40000 *The optimal dilutions should be determined by the end user. Reactivity: Human,Mouse Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific). Specificity: MSMB Antibody detects endogenous levels of total MSMB. Immunogen: A synthesized peptide derived from human MSMB, corresponding to a region within the internal amino acids. Uniprot: P08118 Description: The protein encoded by this gene is a member of the immunoglobulin binding factor family. It is synthesized by the epithelial cells of the prostate gland and secreted into the seminal plasma. This protein has inhibin-like activity. It may have a role as an autocrine paracrine factor in uterine, breast and other female reproductive tissues. The expression of the encoded protein is found to be decreased in prostate cancer. Two alternatively spliced transcript variants encoding different isoforms are described for this gene. The use of alternate polyadenylation sites has been found for this gene. Storage Condition and Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM Buffer: NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt. Western blot analysis of HepG2 cell lysates, using MSMB Antibody. The lane on the left was treated with the antigen- specific peptide. 1 / 2 Affinity Biosciences website:www.affbiotech.com order:[email protected] DF6720 at 1/100 staining Mouse liver tissue by IHC-P. -
Association of Imputed Prostate Cancer Transcriptome with Disease Risk Reveals Novel Mechanisms
Corrected: Author Correction ARTICLE https://doi.org/10.1038/s41467-019-10808-7 OPEN Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms Nima C. Emami1,2, Linda Kachuri2, Travis J. Meyers2, Rajdeep Das3,4, Joshua D. Hoffman2, Thomas J. Hoffmann 2,5, Donglei Hu 5,6,7, Jun Shan8, Felix Y. Feng3,4,7, Elad Ziv5,6,7, Stephen K. Van Den Eeden 3,8 & John S. Witte1,2,3,5,7 1234567890():,; Here we train cis-regulatory models of prostate tissue gene expression and impute expression transcriptome-wide for 233,955 European ancestry men (14,616 prostate cancer (PrCa) cases, 219,339 controls) from two large cohorts. Among 12,014 genes evaluated in the UK Biobank, we identify 38 associated with PrCa, many replicating in the Kaiser Permanente RPGEH. We report the association of elevated TMPRSS2 expression with increased PrCa risk (independent of a previously-reported risk variant) and with increased tumoral expression of the TMPRSS2:ERG fusion-oncogene in The Cancer Genome Atlas, suggesting a novel germline-somatic interaction mechanism. Three novel genes, HOXA4, KLK1, and TIMM23, additionally replicate in the RPGEH cohort. Furthermore, 4 genes, MSMB, NCOA4, PCAT1, and PPP1R14A, are associated with PrCa in a trans-ethnic meta-analysis (N = 9117). Many genes exhibit evidence for allele-specific transcriptional activation by PrCa master-regulators (including androgen receptor) in Position Weight Matrix, Chip-Seq, and Hi-C experimental data, suggesting common regulatory mechanisms for the associated genes. 1 Program in Biological and Medical Informatics, University of California San Francisco, San Francisco, CA 94158, USA. -
Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer Jun A, Baotong Zhang, Zhiqian Zhang, Jin-Tang Dong
Supplementary Materials: Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer Jun A, Baotong Zhang, Zhiqian Zhang, Jin-Tang Dong Figure S1. Overlap differentially expressed genes (DEGs) between our study and previously re- ported microarray experiments. Figure S2. The diagnosis effectiveness of the six CRPCPS genes. ROC curves for the six CRPCPS genes in the training cohort (a) and the validation cohort (b). Cancers 2021, 13 S2 of S13 Figure S3. Evaluation of the CRPCPS in the internal validation cohort and the entire TCGA cohort. (a) Distribution of CRPCPS score (left), patients’ recurrent status (center), and expression profiles of the six CRPCPS genes (right) in the internal validation cohort. (b) Receiver operating character- istic (ROC) curves were used to evaluate the predictability of RFS at 3-, 5-, and 8-year by the CRPCPS score, Gleason score, and pathological tumor stage in the internal validation cohort. (c) Distribution of CRPCPS score (left), patients' survival status (center), and expression profiles of the six CRPCPS genes that constitute the CRPCPS (right) in the entire TCGA cohort. (d) Receiver oper- ating characteristic (ROC) curves were used to evaluate the predictability of RFS at 3-, 5-, and 8- year by the CRPCPS score, Gleason score, and pathological tumor stage in the entire TCGA cohort. Cancers 2021, 13 S3 of S13 Figure S4. Association of CRPCPS with tumor stage (a-d), Gleason score (e-h), and lymph node status (i-k) in different patient cohorts. Figure S5. Association of CRPCPS with patients’ age in the TCGA training cohort (a), the TCGA validation cohort (b), the entire TCGA cohort (c), the MSKCC cohort (d), the Cambridge cohort (GSE70768) (e), and the Belfast cohort (GSE116918) (f). -
Recurrent Inversion Toggling and Great Ape Genome Evolution
HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 December 15. Published in final edited form as: Nat Genet. 2020 August ; 52(8): 849–858. doi:10.1038/s41588-020-0646-x. Recurrent inversion toggling and great ape genome evolution David Porubsky1,2,9, Ashley D. Sanders3,9, Wolfram Höps3, PingHsun Hsieh1, Arvis Sulovari1, Ruiyang Li1, Ludovica Mercuri4, Melanie Sorensen1, Shwetha C. Murali1,5, David Gordon1,5, Stuart Cantsilieris1,6, Alex A. Pollen7, Mario Ventura4, Francesca Antonacci4, Tobias Marschall8, Jan O. Korbel3, Evan E. Eichler1,5,* 1Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington, USA. 2Max Planck Institute for Informatics, Saarland Informatics Campus E1.4, Saarbrücken, Germany. 3European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany. 4Dipartimento di Biologia, Università degli Studi di Bari “Aldo Moro”, Bari, Italy. 5Howard Hughes Medical Institute, University of Washington, Seattle, Washington, USA. 6Centre for Eye Research Australia, Department of Surgery (Ophthalmology), University of Melbourne, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia. 7Department of Neurology, University of California, San Francisco (UCSF), San Francisco, California, USA. 8Institute for Medical Biometry and Bioinformatics, Medical Faculty, Heinrich Heine University Düsseldorf, Germany. 9These authors contributed equally to this work. Abstract Inversions play an important role in disease and evolution but are difficult to characterize because their breakpoints map to large repeats. We increased by six-fold the number (n = 1,069) of previously reported great ape inversions using Strand-seq and long-read sequencing. We find that the X chromosome is most enriched (2.5-fold) for inversions based on its size and duplication content. -
Alterations in LMTK2, MSMB and HNF1B Gene Expression Are Associated with the Development of Prostate Cancer BMC Cancer 2010, 10:315
Harries et al. BMC Cancer 2010, 10:315 http://www.biomedcentral.com/1471-2407/10/315 RESEARCH ARTICLE Open Access AlterationsResearch article in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer Lorna W Harries*1, John RB Perry2, Paul McCullagh3 and Malcolm Crundwell4 Abstract Background: Genome wide association studies (GWAS) have identified several genetic variants that are associated with prostate cancer. Most of these variants, like other GWAS association signals, are located in non-coding regions of potential candidate genes, and thus could act at the level of the mRNA transcript. Methods: We measured the expression and isoform usage of seven prostate cancer candidate genes in benign and malignant prostate by real-time PCR, and correlated these factors with cancer status and genotype at the GWAS risk variants. Results: We determined that levels of LMTK2 transcripts in prostate adenocarcinomas were only 32% of those in benign tissues (p = 3.2 × 10-7), and that an independent effect of genotype at variant rs6465657 on LMTK2 expression in benign (n = 39) and malignant tissues (n = 21) was also evident (P = 0.002). We also identified that whilst HNF1B(C) and MSMB2 comprised the predominant isoforms in benign tissues (90% and 98% of total HNF1B or MSMB expression), HNF1B(B) and MSMB1 were predominant in malignant tissue (95% and 96% of total HNF1B or MSMB expression; P = 1.7 × 10-7 and 4 × 10-4 respectively), indicating major shifts in isoform usage. Conclusions: Our results indicate that the amount or nature of mRNA transcripts expressed from the LMTK2, HNF1B and MSMB candidate genes is altered in prostate cancer, and provides further evidence for a role for these genes in this disorder. -
Overview of Research on Fusion Genes in Prostate Cancer
2011 Review Article Overview of research on fusion genes in prostate cancer Chunjiao Song1,2, Huan Chen3 1Medical Research Center, Shaoxing People’s Hospital, Shaoxing University School of Medicine, Shaoxing 312000, China; 2Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing 312000, China; 3Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Zhejiang Institute of Microbiology, Hangzhou 310000, China Contributions: (I) Conception and design: C Song; (II) Administrative support: Shaoxing Municipal Health and Family Planning Science and Technology Innovation Project (2017CX004) and Shaoxing Public Welfare Applied Research Project (2018C30058); (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Song; (V) Data analysis and interpretation: H Chen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Chunjiao Song. No. 568 Zhongxing Bei Road, Shaoxing 312000, China. Email: [email protected]. Abstract: Fusion genes are known to drive and promote carcinogenesis and cancer progression. In recent years, the rapid development of biotechnologies has led to the discovery of a large number of fusion genes in prostate cancer specimens. To further investigate them, we summarized the fusion genes. We searched related articles in PubMed, CNKI (Chinese National Knowledge Infrastructure) and other databases, and the data of 92 literatures were summarized after preliminary screening. In this review, we summarized approximated 400 fusion genes since the first specific fusion TMPRSS2-ERG was discovered in prostate cancer in 2005. Some of these are prostate cancer specific, some are high-frequency in the prostate cancer of a certain ethnic group. This is a summary of scientific research in related fields and suggests that some fusion genes may become biomarkers or the targets for individualized therapies. -
Development of a Real-Time PCR Assay for the Detection of Blood, Saliva, and Semen Author(S): Cynthia B
The author(s) shown below used Federal funding provided by the U.S. Department of Justice to prepare the following resource: Document Title: Development of a Real-time PCR Assay for the Detection of Blood, Saliva, and Semen Author(s): Cynthia B. Zeller, Ph.D. Document Number: 251633 Date Received: April 2018 Award Number: 2008-DN-BX-K137 This resource has not been published by the U.S. Department of Justice. This resource is being made publically available through the Office of Justice Programs’ National Criminal Justice Reference Service. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. NATIONAL INSTITUTE OF JUSTICE 2008-DN-BX-K137 Development of a Real-time PCR Assay for the Detection of Blood, Saliva and Semen Cynthia Zeller, Ph.D. [email protected] 410-704-2170 EIN: 526002033 DUNS: 143372741 Towson University College of Graduate Studies and Research and Fisher College of Science and Mathematics Department of Chemistry Forensic Science Program 8000 York Rd. Towson, MD 21252 PROJECT START DATE: November 1, 2008 FINAL REPORT February 28, 2013 Cynthia B. Zeller, Ph.D Principal Investigator 1 ABSTRACT During the process of forensic DNA genotyping, evidence containing potential DNA evidence undergoes serological screening to determine which body fluid, if any, it contains. The majority of the DNA genotyping process has under gone automation, leaving a bottleneck at the serological analysis stage. This is due in large part to the methods employed to identify body fluids. Since most of the commonly used assays test for the presence or function of a particular protein prevalent in a specific body fluid, these tests cannot be multiplexed and therefore can use a fairly large portion of a stain if multiple body fluids need to be identified. -
Prenatal Diagnosis of Small Supernumerary Marker Chromosome 10 by Array-Based Comparative Genomic Hybridization and Microdissected Chromosome Sequencing
biomedicines Article Prenatal Diagnosis of Small Supernumerary Marker Chromosome 10 by Array-Based Comparative Genomic Hybridization and Microdissected Chromosome Sequencing Igor N. Lebedev 1,* , Tatyana V. Karamysheva 2 , Eugeny A. Elisaphenko 2, Alexey I. Makunin 3 , Daria I. Zhigalina 1, Maria E. Lopatkina 1 , Gleb V. Drozdov 1, Aleksander D. Cheremnykh 1, Natalia B. Torkhova 1, Gulnara N. Seitova 1, Stanislav A. Vasilyev 1 , Anna A. Kashevarova 1, Ludmila P. Nazarenko 1 and Nikolay B. Rubtsov 2,4 1 Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia; [email protected] (D.I.Z.); [email protected] (M.E.L.); [email protected] (G.V.D.); [email protected] (A.D.C.); [email protected] (N.B.T.); [email protected] (G.N.S.); [email protected] (S.A.V.); [email protected] (A.A.K.); [email protected] (L.P.N.) 2 Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; [email protected] (T.V.K.); [email protected] (E.A.E.); [email protected] (N.B.R.) 3 Wellcome Sanger Institute, Cambridge CB101SA, UK; [email protected] Citation: Lebedev, I.N.; Karamysheva, 4 Department of Cytology and Genetics, Novosibirsk State University, 630090 Novosibirsk, Russia T.V.; Elisaphenko, E.A.; Makunin, A.I.; * Correspondence: [email protected]; Tel.: +7-38-2251-1109 Zhigalina, D.I.; Lopatkina, M.E.; Drozdov, G.V.; Cheremnykh, A.D.; Abstract: Interpreting the clinical significance of small supernumerary marker chromosomes (sSMCs) Torkhova, N.B.; Seitova, G.N.; et al. -
Phenotype Informatics
Freie Universit¨atBerlin Department of Mathematics and Computer Science Phenotype informatics: Network approaches towards understanding the diseasome Sebastian Kohler¨ Submitted on: 12th September 2012 Dissertation zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) am Fachbereich Mathematik und Informatik der Freien Universitat¨ Berlin ii 1. Gutachter Prof. Dr. Martin Vingron 2. Gutachter: Prof. Dr. Peter N. Robinson 3. Gutachter: Christopher J. Mungall, Ph.D. Tag der Disputation: 16.05.2013 Preface This thesis presents research work on novel computational approaches to investigate and characterise the association between genes and pheno- typic abnormalities. It demonstrates methods for organisation, integra- tion, and mining of phenotype data in the field of genetics, with special application to human genetics. Here I will describe the parts of this the- sis that have been published in peer-reviewed journals. Often in modern science different people from different institutions contribute to research projects. The same is true for this thesis, and thus I will itemise who was responsible for specific sub-projects. In chapter 2, a new method for associating genes to phenotypes by means of protein-protein-interaction networks is described. I present a strategy to organise disease data and show how this can be used to link diseases to the corresponding genes. I show that global network distance measure in interaction networks of proteins is well suited for investigat- ing genotype-phenotype associations. This work has been published in 2008 in the American Journal of Human Genetics. My contribution here was to plan the project, implement the software, and finally test and evaluate the method on human genetics data; the implementation part was done in close collaboration with Sebastian Bauer. -
The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
biomedicines Article The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy Zlata Huskova 1 , Jana Knillova 1, Zdenek Kolar 1, Jana Vrbkova 2, Milan Kral 3,* and Jan Bouchal 1,* 1 Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic; [email protected] (Z.H.); [email protected] (J.K.); [email protected] (Z.K.) 2 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic; [email protected] 3 Department of Urology, University Hospital, 779 00 Olomouc, Czech Republic * Correspondence: [email protected] (M.K.); [email protected] (J.B.) Received: 28 April 2020; Accepted: 23 June 2020; Published: 25 June 2020 Abstract: The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5–10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed.